Navigation Links
Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
Date:9/27/2007

Summary: Genmab has Amended the Design of the Ofatumumab Pivotal Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced the

Number of Patients to Approximately 81

COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has amended the design of an ongoing pivotal study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin's lymphoma (NHL) to a single arm trial that will now include approximately 81 patients. All patients will receive one infusion of 300 mg of ofatumumab followed by 7 weekly infusions of 1000 mg of ofatumumab. The original study design included 162 patients, who would have received one infusion of 300 mg of ofatumumab followed by 7 weekly infusions of either 500 or 1000 mg of ofatumumab. This is the first study of ofatumumab dedicated to patients with rituximab-refractory follicular lymphoma.

In order to establish that ofatumumab is efficacious in this refractory setting, reducing the number of patients in the trial will help to expedite a result. The lower dose (500 mg) was dropped to reduce the total number of patients to be accrued and ensure that these very sick patients receive the maximum dose. Data from patients who were already treated in the 500 mg dose group will be analyzed for safety and included in the secondary efficacy analysis, but will not be included in the primary efficacy analysis.

"This change to the pivotal study design will allow us to treat all the refractory patients with a higher dose level of ofatumumab, allowing the maximum opportunity for response and longer lasting effects in this patient population," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. Ofatumumab is an investigational drug being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any market.

About Genmab A/S

Genmab is a leading int
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. Enzyme Immunoassay for Studying Intracellular Levels of cAMP
4. RT-PCR Primers for the Study of Apoptosis
5. A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7 Cell Lines
6. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
7. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
8. Medical College receives $377K to study brain disease
9. Kauffman study shows consistent entrepreneurial growth
10. Study affirms information technology-productivity link
11. Deltanoid Pharmaceuticals begins phase II osteoporosis study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 PrimeSource Building ... materials, selected SoundConnect to support their ... based audio and web conferencing platform GlobalMeet powered ... PrimeSource’s employees’ needs. SoundConnect delivers award winning ... PrimeSource Building Products will be utilizing GlobalMeet ...
(Date:8/27/2014)... Varian Medical Systems today broke ground ... Lake City manufacturing facility and allow for the consolidation ... create 1,000 new full time jobs in the state ... home to hardworking people with immense engineering and technical ... success in the manufacturing of our state-of-the-art X-ray technology,” ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... mysteries is how plants survive impact by the ... rays, while using this energy for photosynthesis. The ... plant,s blades quickly dissipate the energy throughout the ... at DTU Physics have now managed to successfully ... bacteria contain light-absorbing proteins which play a role ...
Breaking Biology Technology:PrimeSource Chooses SoundConnect as Collaboration Provider 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3DTU researchers film protein quake for the first time 2
... MISSISSAUGA, ON, Dec. 14 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and advances ... stages of development, today announced that it has priced ... a price to the public of $1.60 per share. ...
... CAMBRIDGE, Mass., Dec. 14, 2010 Tolerx, Inc., a ... and cancer by modulating T cell activity, today announced ... to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles ... immune system by enabling T cells to more effectively ...
... Cambridge, Mass., December 6, 2010 Utilizing a century-old ... at Harvard University have demonstrated, for the first time, ... collaboration with researchers from Hamamatsu Photonics in Hamamatsu City, ... University of Magdeburg, Germany, the advance has a wide ...
Cached Biology Technology:YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 2YM BIOSCIENCES PRICES $40 MILLION PUBLIC OFFERING 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3Capasso lab demonstrates highly unidirectional 'whispering gallery' microlasers 2
(Date:8/28/2014)... to Research Careers) Program has announced the travel award ... October 18 22, 2014 in San Diego, California. ... of students, post doctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ... conferred 16 awards totaling $29,600., The FASEB MARC Program ...
(Date:8/28/2014)... Researchers at the University of Minnesota have developed ... to be used for muscle regeneration research as well ... FSHD. , The research is published in the current ... There is no treatment for FSHD, which is thought ... muscular dystrophy. FSHD is an unusual genetic disorder because, ...
(Date:8/28/2014)... support of peer groups and clinicians is critical ... to recent University of Georgia research. , A ... County area determined that role models for successful ... of infants. , "Mothers who received that support ... said study co-author Alex Anderson, an associate professor ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2
... low intake of folate and vitamin B12 increases the ... among nearly 3,000 middle-aged and elderly Finnish subjects. On ... an increased risk for the metabolic syndrome. Based on ... separate depressive subtypes with different etiologies in terms of ...
... This press release is available in Spanish . ... of amino acids and they play a fundamental role in ... in genes; they, therefore, carry out numerous functions in an ... material), bioregulating (they form part of enzymes) and a long ...
... how life began on a molecular level has been a ... on a possible mechanism by which life may have gotten ... early Earth. Researchers have proposed several competing theories for ... before the first genes or living cells came to be. ...
Cached Biology News:Lack of nutrients and metabolic syndrome linked to different subtypes of depression 2Using computational biology for the annotation of proteins 2Using computational biology for the annotation of proteins 3Model sheds light on the chemistry that sparked the origin of life 2
... Tissue Staining Kits are intended for localization ... histological and cytological specimens. These kits may ... by either R&D Systems or by other ... formation of the Avidin-Biotin Complex (ABC) with ...
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... Purification Protocols covers a wide range of ... and experienced researchers in all areas of ... from the books preface illustrates just how ... research library., The chapters introduce the theoretical ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: